 "Glenmark Pharmaceuticals agrees to a million settlement over drug pricing misconduct, reflecting ongoing challenges in the pharmaceutical industry.")
Glenmark Pharmaceuticals agrees to a $25 million settlement over drug pricing misconduct, reflecting ongoing challenges in the pharmaceutical industry.
Glenmark Pharmaceuticals has reached a settlement with the US Department of Justice, agreeing to pay $25 million due to a case involving the pricing of a generic drug. This payment will be made in six installments over five years, accruing interest at a rate of 4.25 percent from May 2024. The settlement, announced in a ...
